The Food and Drug Administration approved a combination of two powerful antiviral drugs to treat liver-destroying hepatitis C, a threapy that promises to be almost 10 times better than standard treatments. The FDA cautioned that Rebetron therapy, manufactured by Schering-Plough, was not a cure and had some serious side-effects.